Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05312892
PHASE1/PHASE2

Sympathetic Mechanisms in Obesity-Crossover Design

Sponsor: Vanderbilt University Medical Center

View on ClinicalTrials.gov

Summary

We will study obese hypertensive subjects in a randomized, crossover study to determine if two weeks sympathetic blockade improves endogenous glucose production. Subjects will be studied on 3 different occasions after two weeks of receiving either placebo, amlodipine (vasodilator arm) or moxonidine (study arm). The order of the studies will be determined using computer-generated randomization. Patients will be blinded as to which treatment they are receiving on each day. An investigator blinded to the treatment assignment will perform the analysis of the data.

Official title: Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity, Crossover Design Study.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2022-05-20

Completion Date

2030-12-31

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

Amlodipine

Subjects will receive either an antihypertensive (amlodipine or moxonidine) medication or placebo for two weeks, then cross over to the second arm, and then after 2 weeks of the second drug/placebo, will be switched to the third arm.

DRUG

Moxonidine

Moxonidine

DRUG

Placebo

Placebo

Locations (1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States